依洛尤单抗对接受他汀治疗患者冠状动脉疾病进展的影响:GLAGOV随机临床试验
GLAGOV多中心双盲安慰剂对照随机试验纳入968例接受他汀治疗的冠状动脉疾病患者,随机接受每月依洛尤单抗420 mg或安慰剂皮下注射76周。依洛尤单抗组较安慰剂组显著降低时间加权平均LDL-C水平(36.6 vs 93.0 mg/dL),并显著减缓冠状动脉斑块进展(PAV变化差异-1.0%),更多患者出现斑块消退。
要点
- 依洛尤单抗组时间加权平均LDL-C为36.6 mg/dL,安慰剂组为93.0 mg/dL,差异-56.5 mg/dL(95%CI -59.7至-53.4;P<.001)。
- PAV安慰剂组增加0.05%,依洛尤单抗组减少0.95%,差异-1.0%(95%CI -1.8%至-0.64%;P<.001)。
- 依洛尤单抗组斑块消退患者比例(PAV)为64.3%,安慰剂组为47.3%,差异17.0%(95%CI 10.4%至23.6%;P<.001)。
核心结论
- 在接受他汀治疗的血管造影冠状动脉疾病患者中,与安慰剂相比,加用依洛尤单抗治疗76周后PAV降低幅度更大。
- 需要进一步研究评估PCSK9抑制对临床结局的影响。
研究设计与样本
- GLAGOV为多中心、双盲、安慰剂对照随机临床试验,纳入968例接受冠状动脉造影的患者。
- 入组时间为2013年5月3日至2015年1月12日,在北美、欧洲、南美、亚洲、澳大利亚和南非的197家学术和社区医院进行。
- 参与者随机接受每月依洛尤单抗420 mg(n=484)或安慰剂(n=484)皮下注射76周,同时使用他汀类药物。
- 主要疗效指标为基线至第78周百分动脉粥样硬化体积(PAV)的名义变化,通过系列血管内超声(IVUS)成像测量。
主要发现
- 968例接受治疗的患者平均年龄59.8岁(SD 9.2),女性269例(27.8%),平均LDL-C水平92.5 mg/dL(SD 27.2),846例在随访时有可评估的成像。
- 依洛尤单抗组时间加权平均LDL-C为36.6 mg/dL,安慰剂组为93.0 mg/dL,差异-56.5 mg/dL(95%CI -59.7至-53.4;P<.001)。
- PAV在安慰剂组增加0.05%,在依洛尤单抗组减少0.95%,差异-1.0%(95%CI -1.8%至-0.64%;P<.001)。
- 归一化总动脉粥样硬化体积(TAV)在安慰剂组减少0.9 mm3,在依洛尤单抗组减少5.8 mm3,差异-4.9 mm3(95%CI -7.3至-2.5;P<.001)。
- 依洛尤单抗组斑块消退患者比例高于安慰剂组:PAV标准为64.3% vs 47.3%(差异17.0%,95%CI 10.4%至23.6%;P<.001),TAV标准为61.5% vs 48.9%(差异12.5%,95%CI 5.9%至19.2%;P<.001)。
关键数值与推荐
- 主要疗效指标PAV变化:依洛尤单抗组-0.95% vs 安慰剂组+0.05%,差异-1.0%(95%CI -1.8%至-0.64%;P<.001)。
- 次要疗效指标归一化TAV变化:依洛尤单抗组-5.8 mm3 vs 安慰剂组-0.9 mm3,差异-4.9 mm3(95%CI -7.3至-2.5;P<.001)。
- 斑块消退(PAV)患者比例:依洛尤单抗组64.3% vs 安慰剂组47.3%,差异17.0%(95%CI 10.4%至23.6%;P<.001)。
- 斑块消退(TAV)患者比例:依洛尤单抗组61.5% vs 安慰剂组48.9%,差异12.5%(95%CI 5.9%至19.2%;P<.001)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 需要进一步研究评估PCSK9抑制对临床结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive statin therapy reduces progression of coronary atherosclerosis in proportion to achieved LDL-C levels. Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors produce incremental LDL-C lowering in statin-treated patients; however, the effects of these drugs on coronary atherosclerosis have not been evaluated. OBJECTIVE: To determine the effects of PCSK9 inhibition with evolocumab on progression of coronary atherosclerosis in statin-treated patients. DESIGN, SETTING, AND PARTICIPANTS: The GLAGOV multicenter, double-blind, placebo-controlled, randomized clinical trial (enrollment May 3, 2013, to January 12, 2015) conducted at 197 academic and community hospitals in North America, Europe, South America, Asia, Australia, and South Africa and enrolling 968 patients presenting for coronary angiography. INTERVENTIONS: Participants with angiographic coronary disease were randomized to receive monthly evolocumab (420 mg) (n = 484) or placebo (n = 484) via subcutaneous injection for 76 weeks, in addition to statins. MAIN OUTCOMES AND MEASURES: The primary efficacy measure was the nominal change in percent atheroma volume (PAV) from baseline to week 78, measured by serial intravascular ultrasonography (IVUS) imaging. Secondary efficacy measures were nominal change in normalized total atheroma volume (TAV) and percentage of patients demonstrating plaque regression. Safety and tolerability were also evaluated. RESULTS: Among the 968 treated patients (mean age, 59.8 years [SD, 9.2]; 269 [27.8%] women; mean LDL-C level, 92.5 mg/dL [SD, 27.2]), 846 had evaluable imaging at follow-up. Compared with placebo, the evolocumab group achieved lower mean, time-weighted LDL-C levels (93.0 vs 36.6 mg/dL; difference, -56.5 mg/dL [95% CI, -59.7 to -53.4]; P < .001). The primary efficacy parameter, PAV, increased 0.05% with placebo and decreased 0.95% with evolocumab (difference, -1.0% [95% CI, -1.8% to -0.64%]; P < .001). The secondary efficacy parameter, normalized TAV, decreased 0.9 mm3 with placebo and 5.8 mm3 with evolocumab (difference, -4.9 mm3 [95% CI, -7.3 to -2.5]; P < .001). Evolocumab induced plaque regression in a greater percentage of patients than placebo (64.3% vs 47.3%; difference, 17.0% [95% CI, 10.4% to 23.6%]; P < .001 for PAV and 61.5% vs 48.9%; difference, 12.5% [95% CI, 5.9% to 19.2%]; P < .001 for TAV). CONCLUSIONS AND RELEVANCE: Among patients with angiographic coronary disease treated with statins, addition of evolocumab, compared with placebo, resulted in a greater decrease in PAV after 76 weeks of treatment. Further studies are needed to assess the effects of PCSK9 inhibition on clinical outcomes. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01813422.
引用
- Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016. PMID: 27846344. doi:10.1001/jama.2016.16951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。